Benefits of stereotactic ablative radiotherapy combined with incomplete transcatheter arterial chemoembolization in hepatocellular carcinoma

Table 2 Prognostic factors for overall survival

Factor	5-year OS (%)	Univariate analysis	Multivariate analysis
Factor	5-year OS (%)	P-value	HR (95 % CI)
Treatment option
Complete TACE	50
TACE + Curative Tx	58	0.843	1.100 (0.521–2.324)
TACE + SABR	53	0.493	1.207 (0.573–2.545)
TACE + Non-curative Tx	28	0.010	2.421 (1.248–4.498)
BCLC stage
0	54
A	42	0.139	-
CTP score
5	48
6	33	0.128	1.037 (0.622–1.729)
7	29	0.013	2.229 (1.147–4.332)
Tumor size (cm)
0.1–3.0	49
3.1–10.0	32	0.008	-

Abbreviations: OS overall survival, TACE transcatheter arterial chemoembolization, Tx treatment, SABR stereotactic ablative radiotherapy, BCLC Barcelona Clinic Liver Cancer, CTP Child-Turcotte-Pugh

ISSN: 1748-717X